Interestingly, in a murine preclinical model of melanoma where anti-CTLA4 treatment alone was not efficient, a combination of IL2 superagonist and anti-CTLA4 led to reduced tumor growth and this effect was abolished when NK cells were depleted [83]. The gene discussed is CTLA4; the disease is neoplasm.